GeneDx Holdings Corp. (WGS) SEC Filings & Earnings Calls

Reimbursement rate pressure

“12% decrease in average reimbursement rates” · word for word

Impairment of acquired assets

“non-cash impairment charges totaling $31.3 million related to the goodwill and intangible assets associated with the Fabric Genomics acquisition.” · word for word

Operating losses and negative cash flow

“Net (loss) income $ (17,740) thousand; Net cash used in operating activities $61.4 million”

GAAP net loss of $17.7M; adjusted net income positive but modest.

“GAAP net loss was $17.7 million.” · word for word

Material Weakness in Internal Controls

“our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of March 31, 2026, because of the material weaknesses in internal control over information technology general controls, or ITGCs previously identified for the year ended December 31, 2025, has not been fully remediated as of Mar” · word for word

Fabric Genomics Acquisition Impairment

“During the first quarter of 2026, the Company concluded that a triggering event had occurred during the period for the goodwill associated with the Fabric Genomics reporting unit primarily due to a downward revision of forecasted cash flows driven by changes in commercial strategy and go-to-market execution, and lower revenue and profitability expectations.” · word for word

Reimbursement Rate Pressure

“5% decrease in average reimbursement rates” · word for word

High Cash Burn Rate

“Net cash used in operating activities $(32.4) million”

Legal Proceedings

“Helo Putative Class Action... parties reached an agreement in principle to resolve all claims for approximately $4.8 million”

Revenue guidance cut indicates potential demand or pricing headwinds despite volume growth.

“Full-year 2026 revenue guidance reduced from $540-555M to $475-490M.”

Adjusted net loss in Q1 and expected adjusted net loss in Q2 suggests path to profitability may be delayed.

“Adjusted net loss of $8.2M in Q1; Q2 guidance of adjusted net loss ~$5M.”

Related party concentration risk

“For the year ended December 31, 2025, we made payments to Twist of approximately $7.4 million for diagnostic kits and lab testing materials.” · word for word

Governance risk from large shareholder influence

“Entities affiliated with Casdin Partners Master Fund, LP ... 11.93% ... Entities affiliated with Corvex Management LP ... 12.60%” · word for word

Compensation risk from high equity dilution

“Equity compensation plan information ... Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights ... 188,632 ... Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans ... 5,276,513”

Debt service costs increase with SOFR+4.5% interest rate; mandatory prepayment provisions could strain cash flow.

“Loan Agreement: 'bears interest at a rate equal to the Term SOFR adjusted secured overnight financing rate plus a margin of 4.50%' and mandatory prepayment provisions.”

Covenants include minimum liquidity of $50M; breach could accelerate repayment.

“Loan Agreement: 'minimum liquidity covenant of $50 million' and events of default.”

Material Weakness in ITGCs

“We have identified a material weakness in our internal control over information technology general controls, or 'ITGCs'.” · word for word

Litigation Exposure

“During the first quarter of 2026, we reached an agreement in principle to resolve all claims for approximately $4.8 million.” · word for word

Dependence on Reimbursement

“We estimate a transaction price in arrangements with third-party insurance payors based on historical collection experience, contractual provisions and insurance reimbursement policies, payor mix, and other relevant information for applicable payor portfolios.” · word for word

Preliminary results subject to audit adjustment; final audited financials may differ.

“The preliminary, unaudited results presented in this press release... are based on current expectations and are subject to adjustment” · word for word

Guidance assumes no material changes in reimbursement or competitive landscape.

“Not explicitly stated but implied by forward-looking statements.”

No significant risks identified; strong execution and demand.

“Volume acceleration coupled with gross margin expansion.” · word for word

Reimbursement Dependency

“The commercial success of our current and future products, if approved, will depend on the extent to which our customers receive coverage and adequate reimbursement from third-party payors.” · word for word

Payor Concentration and Billing Risk

“Third-party payors may decide to deny payment or seek to recoup payments for tests performed by us that they contend were improperly billed, not medically necessary or against their coverage determinations, or for which they believe they have otherwise overpaid.” · word for word

Settlement Payment Obligation

“As of September 30, 2025, remaining payments due to the payor were $12.0 million, with $10.0 million due prior to December 31, 2025.” · word for word